AbbVie (ABBV) Tax Provisions (2012 - 2026)

AbbVie (ABBV) has 15 years of Tax Provisions data on file, last reported at $342.0 million in Q1 2026.

• Quarterly Tax Provisions fell 8.06% year-over-year to $342.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.3 billion (up 501.72% YoY) and the FY2025 annual result came in at $2.4 billion, up 514.74% from the prior year.
• Tax Provisions eased to $342.0 million in Q1 2026 per ABBV's latest filing, from $853.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $853.0 million in Q4 2025 and bottomed at -$2.2 billion in Q4 2024.
• The 5-year median for Tax Provisions is $448.0 million (2022), against an average of $322.5 million.
• Peak annual rise in Tax Provisions reached 202.33% in 2024, while the deepest fall reached 678.87% in 2024.
• Tracing ABBV's Tax Provisions over 5 years: stood at $493.0 million in 2022, then declined by 21.3% to $388.0 million in 2023, then slumped by 678.87% to -$2.2 billion in 2024, then surged by 137.98% to $853.0 million in 2025, then plunged by 59.91% to $342.0 million in 2026.
• Per Business Quant, the three latest ABBV Tax Provisions figures stand at $342.0 million (Q1 2026), $853.0 million (Q4 2025), and $526.0 million (Q3 2025).

Peer Comparison